Document is current
Any future updates will be listed below
-
Authors
Hall, Erin M
Yin, Dwight E
Goyal, Rakesh K
Ahmed, Atif A
Mitchell, Grace S
St. Peter, Shawn D
Flatt, Terrie G
Ahmed, Ibrahim A
Li, Weijie
Hendrickson, Richard J
August, Keith J
Myers, G Doug
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02435849 at ClinicalTrials.govDocuments that mention this clinical trial
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
https://doi.org/10.1136/jitc-2020-001225
Chimeric antigen receptor T cell therapy in childhood leukaemia
https://doi.org/10.1136/archdischild-2024-328263
Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
https://doi.org/10.1136/jitc-2020-002056
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
https://doi.org/10.1200/jco.22.00642
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
https://doi.org/10.1136/jitc-2020-002287
- License Information
